reports
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat L...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis (LN). The Company’s collaboration partner, Otsuka Pharmaceutical Co., Ltd., filed the new drug application (NDA) with Japanese regulatory authorities in November 2023. The approval is based on data from the AURORA Clinical Program, which included a 12-month, P...
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Con...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, September 17-19, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 17th, at 3:05 PM EDT. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found . About Aurinia Aurinia Pharmaceutica...
Aurinia Announces Board Restructuring
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it has restructured its Board of Directors (the Board) to further align the Company with shareholder interests. Peter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director. Mr. Greenleaf had conditionally resigned as a Director because he received less than majority support at the 2024 Annual General Meeting (the Meeting). The Board carefully considered all relevant factors and determined that there are exceptional circumstan...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PHM PULTEGROUP INC.
ZTS ZOETIS INC. CLASS A
WWW WOLVERINE WORLD WIDE INC.
PSA PUBLIC STORAGE
MGPI MGP INGREDIENTS INC.
ERIE ERIE INDEMNITY COMPANY CLASS A
CUBE CUBESMART
CYD CHINA YUCHAI INTERNATIONAL LTD.
LFVN LIFEVANTAGE
TZOO TRAVELZOO
CYH COMMUNITY HEALTH SYSTEMS INC.
SUI SUN COMMUNITIES INC.
AUP AURINIA PHARMACEUTICALS INC.
GIII G-III APPAREL GROUP LTD.
RAIL FREIGHTCAR AMERICA INC.
FCPT FOUR CORNERS PROPERTY TRUST INC.
AGX ARGAN INC.
NATH NATHAN'S FAMOUS INC.
SBAC SBA COMMUNICATIONS CORP. CLASS A
YEXT YEXT
RYTM RHYTHM PHARMACEUTICALS
FRHC FREEDOM HOLDING CORP
TARS TARSUS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
KEQU KEWAUNEE SCIENTIFIC CORP.
ACLX ARCELLX INC
NUVL NUVALENT INC
HOI B HOI PUBLISHING AB
CMPO COMPOSECURE INC
KVUE KENVUE INC
AVBP ARRIVENT BIOPHARMA INC
FOA FINANCE OF AMERICA COMPANIES INC.
CCI CALAMOS GLB CNVRTBL & DYNMC INC COM
ASMB ASSEMBLY BIOSCIENCES INC
Aurinia Announces First Participant Dosed in AUR200 Single Ascending D...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The SAD study will assess the safety, tolerability, pharmacokinetics, and changes in biomarkers for AUR200 in healthy volunteers, with data expected in the first half of 2025. “The start ...
- Dave Nicoski
- Ross LaDuke
ILMN ILLUMINA INC.
KMX CARMAX INC.
TFX TELEFLEX INCORPORATED
OMCL OMNICELL INC.
MDT MEDTRONIC PLC
MD MEDNAX INC.
LAD LITHIA MOTORS INC. CLASS A
JNJ JOHNSON & JOHNSON
GILD GILEAD SCIENCES INC.
EXPE EXPEDIA GROUP INC.
CNMD CONMED CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
BXP BOSTON PROPERTIES INC.
ATSG AIR TRANSPORT SERVICES GROUP INC.
APPS DIGITAL TURBINE
ANGO ANGIODYNAMICS INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
AUP AURINIA PHARMACEUTICALS INC.
CRI CARTER'S INC.
LBRDA LIBERTY BROADBAND CORP. CLASS A
ASIX ADVANSIX INC.
CSCO CISCO SYSTEMS INC.
KREF KKR REAL ESTATE FINANCE TRUST
ROKU ROKU INC. CLASS A
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
NVST ENVISTA HOLDINGS
MTCH MATCH GROUP INC.
GEVO GEVO
CGEM CULLINAN ONCOLOGY INC
OLPX OLAPLEX HLDGS INC
TSE TRINSEO PLC
EXFY EXPENSIFY INC
CCI CALAMOS GLB CNVRTBL & DYNMC INC COM
CSOAD COASTAL CONTACTS INC COM
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investmen...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September 9-11, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat and Q&A session on Tuesday, September 10, at 10:30 AM EST. This session will not include a webcast. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on deliveri...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WLDN WILLDAN GROUP
VIRC VIRCO MANUFACTURING CORP.
TBBK THE BANCORP
PSIX POWER SOLUTIONS INTERNATIONAL INC.
NWPX NORTHWEST PIPE CO.
KTOS KRATOS DEFENSE & SECURITY SOLUTIONS INC.
BFIN BANKFINANCIAL
AXGN AXOGEN INC.
ASPN ASPEN AEROGELS
MG/CN MAGNA INTERNATIONAL INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
AUP AURINIA PHARMACEUTICALS INC.
GLOB GLOBANT SA
NGS NATURAL GAS SERVICES GROUP INC.
SGMS SCIENTIFIC GAMES CORPORATION
HRB H&R BLOCK INC.
MHH MASTECH DIGITAL
KINS KINGSTONE COS. INC.
FEIM FREQUENCY ELECTRONICS INC.
SIGA SIGA TECHNOLOGIES INC.
SNFCA SECURITY NATIONAL FINANCIAL CORP. CL A
PSNL PERSONALIS
VHI VALHI INC.
KLXE KLX ENERGY SERVICES
MSGE MADISON SQUARE GARDEN ENTERTAINMENT
CLBT CELLEBRITE DI LTD
CINT CI&T INC
RKLB ROCKET LAB USA INC
PGRU PROPERTYGURU GROUP LTD
COHR COHERENT CORP
REAX ADL VENTURES INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
FIHL FIDELIS INSURANCE HOLDINGS LIMITED
LTH LIFE TIME GROUP HLDGS INC
ANG ANGLOGOLD ASHANTI LIMITED
HG HAMILTON INSURANCE GROUP LTD.
AKA AKA BRANDS HOLDING CORP
UBXG U BX TECHNOLOGY LTD
TEM TEMPUS AI INC
BVS BAYVIEW CAPITAL TRUST I PFD 9.76%
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Fin...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter and six months ended June 30, 2024. Amounts are expressed in U.S. dollars. Total net revenue was $57.2 million for the three months ended June 30, 2024, and $41.5 million for the same period in 2023, representing growth of approximately 38%. Year to date total net revenue was $107.5 million for the six months ended June 30, 2024, compared to $75.9 million for the same period in 2023, representing growth of approxi...
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operat...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Interested participants can dial (866) 682-6100 or (862) 298-0702 (toll-free U.S. & Canada). The audio webcast can also be accessed . A replay of the webcast will be available...
Aurinia to Participate in Upcoming Investor Healthcare Conferences
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, July 9-10, 2024, in Boston, and at the 3rd Annual H.C. Wainwright Virtual Kidney Conference, July 15, 2024. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In J...
Aurinia Announces 2024 Annual General Meeting Results
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of Directors (the Board). The four directors, while elected under applicable corporate law, who received less than majority support are Peter Greenleaf, Director, President and CEO; Daniel G. Billen, Ph.D., Director, Chair of the Board, Chair of the Compensation Committee, and Member ...
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People w...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with active lupus nephritis (LN). A propensity analysis comparing the pooled AURA-LV and AURORA 1 studies ...
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued the following letter to shareholders in response to a letter from Lucien Selce. Dear Fellow Shareholders: Aurinia’s Board of Directors and management team have been taking a range of actions to position the Company for sustainable success and build value for shareholders, while staying true to our core focus of delivering therapies to treat targeted patient populations with high unmet medical needs. We believe we have established strong momentum in the bus...
Aurinia Provides Update on Proxy Statement
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) filed a supplement (the “Supplement”) to the Company’s Management Information and Proxy Statement dated June 3, 2024 (the “Proxy Statement/Circular”) for its Annual General Meeting of Shareholders to be held on June 14, 2024 (the “Annual Meeting”). The purpose of the Supplement is to reduce the proposed increase in the shares reserved for issuance under the Company’s Equity Incentive Plan in Proposal 4 from 11,375,000 Plan Shares (as defined in the Proxy Statement/Circul...
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 Jefferies Global Healthcare Conference in New York from June 4-6, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a presentation on Wednesday, June 5, from 8:00 to 8:25 AM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical co...
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nep...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program. Economic modeling by the Institute for Clinical and Economic Review (ICER) in March 2021 demonstrated the cost-effect...
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for Pe...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of two studies at the annual Congress of Clinical Rheumatology (CCR) East 2024 taking place in Destin, FL, May 9-12. The data reinforce previous findings on the safety and effectiveness of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), in combination with MMF and steroids, for the treatment of adult patients with active lupus nephritis (LN), as shown in the AURORA Clinical Program. A propensity analysis of the A...
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Confere...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Aurinia management will host one-on-one meetings with investors and will participate in a fireside chat on Wednesday, May 15, from 10:00 to 10:25 AM Eastern Time. A live webcast of the session will be available on the Investor section of Aurinia’s website, which can be found About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharm...
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Opera...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2024. Amounts are expressed in U.S. dollars. Total net revenue was $50.3 million for the three months ended March 31, 2024 and $34.4 million for the same period in 2023. representing growth of approximately 46%. Net product revenue was $48.1 million for the three months ended March 31, 2024 and $34.3 million for the same period in 2023, representing growth of approximately 40%. Aurinia rapidly com...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.